Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis

The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Moss, Nelson S., Singh, Jolene M., Reiner, Anne S., Drago, Joshua Z., Modi, Shanu, Seidman, Andrew D., Chandarlapaty, Sarat, Ross, Dara S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590773/
https://www.ncbi.nlm.nih.gov/pubmed/37867174
http://dx.doi.org/10.1038/s41523-023-00592-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590773/
https://www.ncbi.nlm.nih.gov/pubmed/37867174
http://dx.doi.org/10.1038/s41523-023-00592-5

Ejemplares similares